Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Duchenne muscular dystrophy (DMD) is a lethal muscle disease for which an effective treatment is urgently needed. The use of stem cells to produce normal muscle cells to replace the missing dystrophin protein has attracted much attention. Claims of success using stem cell treatment in animal models of human muscle diseases require careful evaluation and are not necessarily easily extrapolated to the clinical situation. Recent studies in the dystrophic dog model have been claimed to show that injected mesangioblasts, stem cells derived from blood vessels, reduce the severity of the disease. However, the authors' interpretation of the results did not consider that benefits might arise from the concomitant use of immunosuppressive drugs alone.

Original publication

DOI

10.1016/j.nmd.2007.01.007

Type

Journal article

Journal

Neuromuscul Disord

Publication Date

03/2007

Volume

17

Pages

206 - 208

Keywords

Animals, Humans, Immunosuppressive Agents, Muscular Dystrophy, Duchenne, Stem Cell Transplantation, Stem Cells